RESUMO

Introducción: La enfermedad por hígado graso no alcohólico es una de las principales causas de afección hepática. La citoqueratina 18 surge como marcador no invasivo para la valoración de fibrosis hepática. El objetivo del trabajo fue validar el uso de la citoqueratina 18 en sangre periférica en el diagnóstico y evolución de los pacientes con enfermedad por hígado graso no alcohólico. Metodología: Para validar la citoqueratina 18 en el diagnóstico se realizó un estudio de tipo caso-control. El grupo caso fueron los pacientes mayores de 18 años, de ambos sexos, con diagnóstico de enfermedad por hígado graso no alcohólico vinculado al síndrome metabólico, captados entre 2/2/2019 al 2/2/2020. El grupo control fueron personas donantes de sangre. Se parearon 1-1 por edad y sexo. Se cuantificó la citoqueratina 18 en sangre periférica de ambos grupos. Para validar la citoqueratina 18 en la evolución de los pacientes con enfermedad de hígado graso no alcohólico se realizó un trabajo prospectivo, longitudinal. El grupo de pacientes captados fueron seguidos durante un año bajo tratamiento estándar, finalizando el mismo se realizó la cuantificación de citoqueratina 18 en sangre periférica. Las variables continuas se expresan con la media y desvío estándar. Se analizó con test de t Student, error α < 5% Resultados: 13 pacientes integran el grupo caso (12 mujeres), de 53 ± 11 años, con IMC 35.01 ± 8.9 kg/m2. El valor de citoqueratina 18 pre-tratamiento fue de 1410 ± 120 UI, y el valor post-tratamiento fue de 117 ± 56, p < 0,005.El grupo control fueron 13 personas (12 mujeres), de 43,4 ± 8,1 años e IMC 28,10 ± 5,4 kg/m2 El valor de citoqueratina 18 fue de 193 ± 7.2 UI, p < 0.005 vs grupo caso pretratamiento. Conclusiones: La citoqueratina 18 es más elevada en los pacientes con enfermedad hígado graso no alcohólico, siendo estadísticamente significativa y disminuye con el tratamiento con significación estadística, pudiendo constituirse en un marcador útil en este grupo de pacientes.

Introduction: Nonalcoholic fatty liver disease is one of the main causes of liver disease. Cytokeratin 18 emerges as a non-invasive marker for the assessment of liver fibrosis. The objective of the work was to validate the use of cytokeratin 18 in peripheral blood in the diagnosis and evolution of patients with non-alcoholic fatty liver disease. Methodology: To validate cytokeratin 18 in the diagnosis, a case-control study was carried out. The case group was patients over 18 years of age, of both sexes, with a diagnosis of non-alcoholic fatty liver disease linked to metabolic syndrome, recruited between 2/2/2019 to 2/2/2020. The control group were blood donors. They were matched 1-1 for age and sex. Cytokeratin 18 was quantified in peripheral blood of both groups. To validate cytokeratin 18 in the evolution of patients with non-alcoholic fatty liver disease, a prospective, longitudinal study was carried out. The group of patients recruited were followed for one year under standard treatment, at the end of which cytokeratin 18 was quantified in peripheral blood. Continuous variables are expressed with the mean and standard deviation. It was analyzed with Student's t test, α error < 5%. Results: 13 patients make up the case group (12 women), 53 ± 11 years old, with BMI 35.01 ± 8.9 kg/m2. The pre-treatment cytokeratin 18 value was 1410 ± 120 IU, and the post-treatment value was 117 ± 56, p < 0.005. The control group was 13 people (12 women), 43.4 ± 8.1 years and BMI 28.10 ± 5.4 kg/m2 The cytokeratin 18 value was 193 ± 7.2 IU, p < 0.005 vs. pretreatment case group. Conclusions: Cytokeratin 18 is higher in patients with non-alcoholic fatty liver disease, being statistically significant, and decreases with treatment with statistical significance, and may become a useful marker in this group of patients.

Introdução: A doença hepática gordurosa não alcoólica é uma das principais causas de doença hepática. A citoqueratina 18 surge como um marcador não invasivo para avaliação de fibrose hepática. O objetivo do trabalho foi validar o uso da citoqueratina 18 no sangue periférico no diagnóstico e evolução de pacientes com doença hepática gordurosa não alcoólica. Metodologia: Para validar a citoqueratina 18 no diagnóstico, foi realizado um estudo caso-controle. O grupo caso foi composto por pacientes maiores de 18 anos, de ambos os sexos, com diagnóstico de doença hepática gordurosa não alcoólica ligada à síndrome metabólica, recrutados entre 02/02/2019 a 02/02/2020. O grupo controle eram doadores de sangue. Eles foram comparados em 1 a 1 por idade e sexo. A citoqueratina 18 foi quantificada no sangue periférico de ambos os grupos. Para validar a citoqueratina 18 na evolução de pacientes com doença hepática gordurosa não alcoólica, foi realizado um estudo prospectivo e longitudinal. O grupo de pacientes recrutados foi acompanhado durante um ano sob tratamento padrão, ao final do qual a citoqueratina 18 foi quantificada no sangue periférico. As variáveis ​​contínuas são expressas com média e desvio padrão. Foi analisado com teste t de Student, erro α < 5%. Resultados: Compõem o grupo caso 13 pacientes (12 mulheres), 53 ± 11 anos, com IMC 35,01 ± 8,9 kg/m2. O valor de citoqueratina 18 pré-tratamento foi de 1410 ± 120 UI e o valor pós-tratamento foi de 117 ± 56, p < 0,005. O grupo controle foi de 13 pessoas (12 mulheres), 43,4 ± 8,1 anos e IMC 28,10 ± 5,4 kg/m2 O valor da citoqueratina 18 foi de 193 ± 7,2 UI, p < 0,005 vs. grupo de casos pré-tratamento. Conclusões: A citoqueratina 18 é maior em pacientes com doença hepática gordurosa não alcoólica, sendo estatisticamente significativa, e diminui com o tratamento com significância estatística, podendo se tornar um marcador útil neste grupo de pacientes.

RESUMO

Hábitos alimentares inadequados, sedentarismo e a maior expectativa de vida da população contribuem significativamente para a prevalência da síndrome metabólica. Essa doença predispõe uma pessoa a desenvolver diabetes mellitus tipo 2 e doenças cardiovasculares, as quais têm um amplo impacto na saúde pública, induzindo sobrecarga no sistema de saúde e reduzindo a qualidade de vida dos indivíduos afetados. A síndrome metabólica é uma doença multifatorial e está relacionada ao processo de envelhecimento, contudo, ainda há uma lacuna significativa, em termos de estudos, sobre a prevalência da condição em populações idosas. Nesse contexto, o presente estudo objetivou rastrear a prevalência da síndrome metabólica em participantes da Universidade Aberta da Terceira Idade (UNATI), localizada em Francisco Beltrão, Paraná. Os critérios diagnósticos de síndrome metabólica abordados nesta pesquisa incluem: circunferência abdominal ≥ 90 cm para homens e ≥ 80 cm para mulheres, triglicerídeos ≥ 150 mg/dL, HDL ≤ 40 mg/dL para homens e ≤ 50 mg/dL para mulheres, pressão arterial sistólica ≥ 130 mmHg e/ou pressão arterial diastólica ≥ 85 mmHg ou estar em farmacoterapia para hipertensão, além de glicemia de jejum ≥ 100 mg/dL ou estar em tratamento farmacológico para diabetes. Um total de 44 idosos foram avaliados, apresentando uma média de idade de 66,9 ± 7,1 anos, com uma predominância de mulheres (88%). Os resultados revelaram uma prevalência alarmante de síndrome metabólica, atingindo 36,4% da amostra estudada. Além disso, observou-se uma alta prevalência de condições associadas, como hipertensão arterial (67,2%), sobrepeso (58,6%) e obesidade visceral (31%). Esses achados ressaltam a importância da implementação de medidas preventivas direcionadas à promoção da qualidade de vida saudável e ao controle dos fatores de risco metabólicos.

Inadequate dietary habits, sedentary lifestyle, and increased life expectancy significantly contribute to the prevalence of metabolic syndrome. This condition predisposes an individual to develop type 2 diabetes mellitus and cardiovascular diseases, which have a broad impact on public health, inducing a burden on the healthcare system and reducing the quality of life of affected individuals. Metabolic syndrome is a multifactorial disease and is related to the aging process; however, there is still a significant gap in terms of studies on the prevalence of the condition in elderly populations. In this context, this study aimed to screen the prevalence of metabolic syndrome in participants of the Open University for the Third Age (UNATI), located in Francisco Beltrão, Paraná. The diagnostic criteria for metabolic syndrome addressed in this research include: abdominal circumference ≥ 90 cm for men and ≥ 80 cm for women, triglycerides ≥ 150 mg/dL, HDL ≤ 40 mg/dL for men and ≤ 50 mg/dL for women, systolic blood pressure ≥ 130 mmHg and/or diastolic blood pressure ≥ 85 mmHg or being on pharmacotherapy for hypertension, in addition to fasting glucose ≥ 100 mg/dL or being on pharmacological treatment for diabetes. A total of 44 elderly individuals were evaluated, with a mean age of 66.9 ± 7.1 years, predominantly women (88%). The results revealed an alarming prevalence of metabolic syndrome, affecting 36.4% of the studied sample. Furthermore, a high prevalence of associated conditions was observed, such as arterial hypertension (67.2%), overweight (58.6%), and visceral obesity (31%). These findings underscore the importance of implementing preventive measures aimed at promoting healthy lifestyles and controlling metabolic risk factors.

Assuntos

RESUMO

El síndrome metabólico (SM) se previene controlando sus factores de riesgo, el programa de reforma de vida (PRV) busca el control y regulación de estos. Objetivo: evaluar el impacto del PRV. Materiales y métodos: Investigación aplicativo, longitudinal, prospectivo, diseño longitudinal, inductivo y deductivo, en una población inicial de 104 trabajadores de una universidad del Perú, la población final fue 31 quienes completaron el programa, los factores de riesgo fueron evaluados por un laboratorista clínico, se utilizó fichas de recolección y se procesó con el programa SPSS V.26, prueba de Wilcoxon y T de Student según el criterio de normalidad. Resultados: el PRV disminuye los niveles de triglicéridos, promedio antes 235,6 mg/dl y después 196,1 mg/dl, no se evidencio efectos positivos en el resto de los factores de riesgo. En personas con algún factor de riesgo el PRV impacto positivamente; antes del PRV 2 personas tenían la glucosa >= a 100 mg/dl y después del PRV 1, en cuanto al perímetro abdominal ≥ 90cm M, ≥ 80cm F antes (30), después (19), presión arterial ≥130/85 mmHg antes (06), después (0), triglicéridos ≥ 150 mg/dl antes (30), después (17), C-HDL < 40 M < 50 F antes (29), después (24). Con un p valor de 0,004 el PRV disminuye los niveles de triglicéridos. Conclusión: En la población en general el PRV disminuye el nivel de triglicéridos; en personas con algún factor de riesgo el PRV controla y regula todos los factores SM

Metabolic syndrome (MS) is prevented by controlling its risk factors; the lifestyle reform program (LRP) seeks to control and regulate them. Objective: to evaluate the impact of the LRP. Materials and methods: Applied, longitudinal, prospective, longitudinal, inductive and deductive design, in an initial population of 104 workers of a Peruvian university, the final population was 31 who completed the program, the risk factors were evaluated by a clinical laboratorist, collection cards were used and processed with the SPSS V.26 program, Wilcoxon and Student's t-test according to the normality criterion. Results: the PRV decreases triglyceride levels, average before 235,6 mg/dl and after 196,1 mg/dl; no positive effects were evidenced in the rest of the risk factors. In people with some risk factor the PRV had a positive impact; before the PRV 2 people had glucose >= 100mg/dl and after the PRV 1, regarding abdominal perimeter ≥ 90cm M, ≥ 80cm F before (30), after (19), blood pressure ≥ 130/85 mmHg before (06), after (0), triglycerides ≥ 150mg/dl before (30), after (17), C-HDL < 40 M < 50 F before (29), after (24). With a p value of 0,004 the PRV decreases triglyceride levels. Conclusion: In the general population the PRV decreases the triglyceride level; in people with some risk factor the PRV controls and regulates all the SM factors

A síndrome metabólica (SM) é prevenida através do controlo dos seus factores de risco, o programa de reforma do estilo de vida (PRV) visa o seu controlo e regulação. Objetivo: Avaliar o impacto do PRV. Materiais e métodos: Investigação aplicada, longitudinal, prospetiva, longitudinal, desenho indutivo e dedutivo, numa população inicial de 104 trabalhadores de uma universidade do Peru, a população final foi de 31 que completaram o programa, os factores de risco foram avaliados por um laboratorista clínico, foram utilizadas fichas de recolha e processadas com o programa SPSS V.26, teste de Wilcoxon e teste t de Student de acordo com o critério de normalidade. Resultados: O PRV reduz os níveis de triglicéridos, em média antes 235,6 mg/dl e depois 196,1 mg/dl, não se evidenciando efeitos positivos nos restantes factores de risco. Em pessoas com algum fator de risco o PRV teve um impacto positivo; antes do PRV 2 pessoas tinham glicose >= 100 mg/dl e depois do PRV 1, quanto ao perímetro abdominal ≥90cm M, ≥ 80 cm F antes (30), depois (19), pressão arterial ≥ 130/85 mmHg antes (06), depois (0), triglicéridos ≥ 150 mg/dl antes (30), depois (17), C-HDL < 40 M < 50 F antes (29), depois (24). Com um p-value de 0,004 o PRV diminui os níveis de triglicéridos. Conclusão: Na população em geral, o PRV diminui os níveis de triglicéridos; em pessoas com alguns factores de risco, o PRV controla e regula todos os factores da SM

RESUMO

El síndrome metabólico (SM) se previene controlando sus factores de riesgo, el programa de reforma de vida (PRV) busca el control y regulación de estos. Objetivo: evaluar el impacto del PRV. Materiales y métodos: Investigación aplicativo, longitudinal, prospectivo, diseño longitudinal, inductivo y deductivo, en una población inicial de 104 trabajadores de una universidad del Perú, la población final fue 31 quienes completaron el programa, los factores de riesgo fueron evaluados por un laboratorista clínico, se utilizó fichas de recolección y se procesó con el programa SPSS V.26, prueba de Wilcoxon y T de Student según el criterio de normalidad. Resultados: el PRV disminuye los niveles de triglicéridos, promedio antes 235,6 mg/dl y después 196,1 mg/dl, no se evidencio efectos positivos en el resto de los factores de riesgo. En personas con algún factor de riesgo el PRV impacto positivamente; antes del PRV 2 personas tenían la glucosa >= a 100 mg/dl y después del PRV 1, en cuanto al perímetro abdominal ≥ 90cm M, ≥ 80cm F antes (30), después (19), presión arterial ≥130/85 mmHg antes (06), después (0), triglicéridos ≥ 150 mg/dl antes (30), después (17), C-HDL < 40 M < 50 F antes (29), después (24). Con un p valor de 0,004 el PRV disminuye los niveles de triglicéridos. Conclusión: En la población en general el PRV disminuye el nivel de triglicéridos; en personas con algún factor de riesgo el PRV controla y regula todos los factores SM.

Metabolic syndrome (MS) is prevented by controlling its risk factors; the lifestyle reform program (LRP) seeks to control and regulate them. Objective: to evaluate the impact of the LRP. Materials and methods: Applied, longitudinal, prospective, longitudinal, inductive and deductive design, in an initial population of 104 workers of a Peruvian university, the final population was 31 who completed the program, the risk factors were evaluated by a clinical laboratorist, collection cards were used and processed with the SPSS V.26 program, Wilcoxon and Student's t-test according to the normality criterion. Results: the PRV decreases triglyceride levels, average before 235,6 mg/dl and after 196,1 mg/dl; no positive effects were evidenced in the rest of the risk factors. In people with some risk factor the PRV had a positive impact; before the PRV 2 people had glucose >= 100mg/dl and after the PRV 1, regarding abdominal perimeter ≥ 90cm M, ≥ 80cm F before (30), after (19), blood pressure ≥ 130/85 mmHg before (06), after (0), triglycerides ≥ 150mg/dl before (30), after (17), C-HDL < 40 M < 50 F before (29), after (24). With a p value of 0,004 the PRV decreases triglyceride levels. Conclusion: In the general population the PRV decreases the triglyceride level; in people with some risk factor the PRV controls and regulates all the SM factors.

A síndrome metabólica (SM) é prevenida através do controlo dos seus factores de risco, o programa de reforma do estilo de vida (PRV) visa o seu controlo e regulação. Objetivo: Avaliar o impacto do PRV. Materiais e métodos: Investigação aplicada, longitudinal, prospetiva, longitudinal, desenho indutivo e dedutivo, numa população inicial de 104 trabalhadores de uma universidade do Peru, a população final foi de 31 que completaram o programa, os factores de risco foram avaliados por um laboratorista clínico, foram utilizadas fichas de recolha e processadas com o programa SPSS V.26, teste de Wilcoxon e teste t de Student de acordo com o critério de normalidade. Resultados: O PRV reduz os níveis de triglicéridos, em média antes 235,6 mg/dl e depois 196,1 mg/dl, não se evidenciando efeitos positivos nos restantes factores de risco. Em pessoas com algum fator de risco o PRV teve um impacto positivo; antes do PRV 2 pessoas tinham glicose >= 100 mg/dl e depois do PRV 1, quanto ao perímetro abdominal ≥90cm M, ≥ 80 cm F antes (30), depois (19), pressão arterial ≥ 130/85 mmHg antes (06), depois (0), triglicéridos ≥ 150 mg/dl antes (30), depois (17), C-HDL < 40 M < 50 F antes (29), depois (24). Com um p-value de 0,004 o PRV diminui os níveis de triglicéridos. Conclusão: Na população em geral, o PRV diminui os níveis de triglicéridos; em pessoas com alguns factores de risco, o PRV controla e regula todos os factores da SM.

RESUMO

BACKGROUND & AIMS: Asprosin is a promising candidate for novel treatments for metabolic-endocrine disorders. The objective of this systematic review and meta-analysis was to consolidate the existing evidence regarding asprosin levels in patients diagnosed with type 2 diabetes (T2D), metabolic syndrome (MetS), and obesity. METHODS: Scopus, Embase, PubMed, Ovid/Medline, and Web of Science were systematically searched without restrictions. We only used the standardized mean differences (SMD) with their 95 % confidence intervals (95 % CI) as the effect measure. A random-effects model (DerSimonian and Laird method) was used for the meta-analysis. Risk of bias was assessed with the Newcastle-Ottawa Scale and Newcastle-Ottawa Scale for Cross-Sectional Studies. RESULTS: Twenty-six studies (n = 3,787) were included in the meta-analysis. Participants with T2D had higher asprosin values than those without T2D (SMD: 1.64; 95 % CI: 1.08-2.21; I2 = 97 %). Patients with MetS had higher asprosin levels compared to those without MetS (SMD: 0.99; 95 % CI: 0.34-1.64; I2 = 96 %). Patients with obesity had higher asprosin levels than participants without obesity (SMD: 1.49; 95 % CI: 0.23-2.76; I2 = 98 %). CONCLUSIONS: Asprosin is significantly higher in patients with either T2D, MetS, or obesity, compared with controls.

RESUMO

Multifunctional peptides derived from various food sources, including ancestral grains, hold significant promise for managing metabolic syndrome. These bioactive peptides exhibit diverse properties that collectively contribute to improving the components of metabolic syndrome. In this study, we investigated the in vitro multifunctionality of six peptides (PW, PM, SW, PPG, PW, and IW) identified through in silico analysis and chemically synthesized. These peptides were evaluated for their potential to address metabolic syndrome-related activities such as antidiabetic, antiobesity, antihypertensive, and antioxidative properties. Assessment included their capacity to inhibit key enzymes associated with these activities, as well as their free radical scavenging and cellular antioxidative activities. Principal component analysis was employed to cluster the peptides according to their multifunctionality. Our results revealed that peptides containing tryptophan (SW, PW, and IW) exhibited the most promising multifunctional attributes, with SW showing particularly high potential. This multifunctional peptide represents a promising avenue for addressing metabolic syndrome.

Assuntos

RESUMO

Background: Metabolic syndrome (MetS) in children is a rising health issue that is strongly associated with cardiovascular diseases and type 2 diabetes mellitus development. Low-affinity antibodies reactive to leptin and ghrelin are suggested to regulate hormone stability and function; nevertheless, the role of the leptin/ghrelin axis and antibodies reactive to both hormones in relation to MetS or its components in the pediatric population remains unknown. Methods: Fifty-eight children (7-12 years) were included and categorized according to the presence of one or more criteria for the diagnosis of MetS or according to body mass index. Body composition, biochemical variables, and metabolic risk indexes were determined. Antibodies reactive to leptin and ghrelin were quantified by an in-house enzyme-linked immunosorbent assay test. Ratios of leptin/ghrelin hormones and anti-leptin/anti-ghrelin immune complexes were obtained. Results: The biochemical variables glucose (P = 0.0009), insulin (P = 0.0001), leptin (P = 0.0036), HOMA-IR (homeostatic model assessment for insulin resistance) (P < 0.0001), and plasma atherogenic index (P < 0.0001) were significantly higher in children with two or three components of MetS (MetS 2-3) in comparison to children with none or one component (MetS 0-1). Ratios of leptin/ghrelin (P = 0.0307) and anti-leptin/anti-ghrelin immune complexes (P = 0.0338) were higher in MetS 2-3 group versus MetS 0-1 group. In MetS 2-3 group, both insulin (r = 0.4361, P = 0.0293) and HOMA-IR (r = 0.4761, P = 0.0161) were positively correlated with the leptin/ghrelin hormone ratio. Conclusions: The higher leptin/ghrelin hormone ratio scores observed in MetS 2-3 group, along with their correlation with insulin levels and HOMA-IR, highlight the role of leptin and ghrelin on insulin sensitivity and metabolic regulation. An increased ratio of anti-leptin/anti-ghrelin immune complexes suggests affinity changes in these antibodies that may lead to alterations in hormone function.

RESUMO

A síndrome metabólica é um distúrbio metabólico complexo, caraterizada pela associação de fatores de risco cardiovascular e resistência à insulina. Na Atenção Primária à Saúde, algumas condições laborais as quais os profissionais estão expostos podem ser fonte de adoecimento, e a literatura evidencia que aspectos laborais estão associados à síndrome metabólica, ou seja, que o contexto ocupacional é capaz de ser um fator de exposição para o desenvolvimento deste problema. O objetivo deste estudo foi estimar a prevalência de síndrome metabólica e os fatores associados em Agentes Comunitários de Saúde de uma cidade do Norte de Minas Gerais, Brasil. Estudo transversal, no qual coletaram dados sociodemográficos, estilo de vida, laborais, antropométricos, bioquímicos e aspectos emocionais. A variável dependente síndrome metabólica foi definida conforme o critério do National Cholesterol Education Program Adult Treatment Panel III. Realizaram-se análises descritivas e de regressão múltipla de Poisson, com variância robusta, considerando um nível de significância de 5% (p<0,05) para o modelo final. Foram avaliados 673 Agentes Comunitários de Saúde, a prevalência de síndrome metabólica foi de 20,8% e associou-se à faixa etária ≥40 anos, menor escolaridade (Fundamental e/ou Médio), sobrepeso/obesidade, lipoproteína de baixa densidade ≥130 mg/dl e proteína C-reativa >5,0 mg/dl. Constatou-se uma elevada prevalência de síndrome metabólica em Agentes Comunitários de Saúde. Verifica-se a necessidade de estudos para o aprofundamento sobre a temática e o desenvolvimento de ações que visem a promoção de hábitos comportamentais saudáveis, bem como a prevenção de fatores de riscos.

Metabolic syndrome is a complex metabolic disorder, characterized by the association of cardiovascular risk factors and insulin resistance. In Primary Health Care, some work conditions to which professionals are exposed can be a source of illness and the literature shows that work aspects are associated with metabolic syndrome, that is, that the occupational context is capable of being an exposure factor for the development of this problem. The objective of this study was to estimate the prevalence of metabolic syndrome and associated factors among community health workers in a city in the North of Minas Gerais, Brazil. Cross-sectional study, in which sociodemographic, lifestyle, work, anthropometric, biochemical, and emotional aspects of data were collected. The dependent variable metabolic syndrome was defined according to the National Cholesterol Education Program Adult Treatment Panel III criteria. Descriptive and multiple Poisson regression analyzes were carried out with robust variance, considering a significance level of 5% (p<0.05) for the final model. 673 community health workers were evaluated, the prevalence of metabolic syndrome was 20.8% and was associated with the age group ≥40 years, lower education (elementary and/or secondary), overweight/obesity, low-density lipoprotein ≥130 mg/dl and C-reactive protein >5.0 mg/dl. A high prevalence of metabolic syndrome was found in community health workers. There is a need for studies to delve deeper into the topic and develop actions aimed at promoting healthy behavioral habits, as well as preventing risk factors.

RESUMO

Objective: To assess the effectiveness of an educational intervention on perceived stress and metabolic syndrome parameters among adults with type 2 diabetes mellitus. Method: Fifty-one adults (aged 48.73±7.84; 86.3% of women) were included in a non-randomized clinical trial performed in a healthcare unit for six months (Brazilian Clinical Trial Registry: RBR-43K52N). All participants were diagnosed with type 2 diabetes mellitus and metabolic syndrome (intervention group, n=26; control group, n=25). The intervention consisted of a nurse-led educational health-promoting program with a multidisciplinary approach organized in seven workshops. The primary outcome was decreased perceived stress, and the secondary outcome was improvement in metabolic syndrome parameters according to perceived stress levels. These outcomes were assessed at two points in time, at the baseline and follow-up. Results: Participation in the intervention program resulted in a significant decrease in perceived stress (p=0.028). The stressed participants in the intervention group experienced a significant decrease in blood glucose levels (p=0.001) and a significant increase in high-density lipoprotein-cholesterol (p=0.003) concentrations after the six-month intervention. Conclusion: The nurse-led educational health-promoting program decreased perceived stress among adults with type 2 diabetes mellitus and metabolic syndrome, improving fasting blood glucose and high-density lipoprotein cholesterol among the stressed participants in the intervention group.

Assuntos

RESUMO

Fibroblast growth factor 19 (FGF19) is a hormone synthesized in enterocytes in response to bile acids. This review explores the pivotal role of FGF19 in metabolism, addressing the urgent global health concern of obesity and its associated pathologies, notably type 2 diabetes. The intriguing inverse correlation between FGF19 and body mass or visceral adiposity, as well as its rapid increase following bariatric surgery, emphasizes its potential as a therapeutic target. This article meticulously examines the impact of FGF19 on metabolism by gathering evidence primarily derived from studies conducted in animal models or cell lines, using both FGF19 treatment and genetic modifications. Overall, these studies demonstrate that FGF19 has antidiabetic and antiobesogenic effects. A thorough examination across metabolic tissues, including the liver, adipose tissue, skeletal muscle, and the central nervous system, is conducted, unraveling the intricate interplay of FGF19 across diverse organs. Moreover, we provide a comprehensive overview of clinical trials involving an FGF19 analog called aldafermin, emphasizing promising results in diseases such as nonalcoholic steatohepatitis and diabetes. Therefore, we aim to foster a deeper understanding of FGF19 role and encourage further exploration of its clinical applications, thereby advancing the field and offering innovative approaches to address the escalating global health challenge of obesity and related metabolic conditions.

Assuntos